Adrian Koh1,2, Paolo Lanzetta3,4, Won Ki Lee5, Chi-Chun Lai6, Wai-Man Chan7, Chung-May Yang8, Chui Ming Gemmy Cheung2,9,10. 1. Eye and Retina Surgeons, Singapore. 2. Singapore National Eye Centre, Singapore. 3. Department of Medical and Biological Sciences - Ophthalmology, University of Udine, Udine, Italy. 4. Istituto Europeo di Microchirurgia Oculare, Udine, Italy. 5. Department of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. 6. Department of Ophthalmology, Chang-Gung Memorial Hospital, Taoyuan, Taiwan. 7. Hong Kong Sanatorium and Hospital, Hong Kong. 8. Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan. 9. Singapore Eye Research Institute, Singapore. 10. Duke-NUS Graduate Medical School, Singapore.
Abstract
PURPOSE: To summarize recommendations for the use of intravitreal aflibercept with a treat-and-extend regimen to manage neovascular age-related macular degeneration (nAMD) in the Asia-Pacific region. Although anti-vascular endothelial growth factor therapies have improved the quality of life of patients with nAMD, a leading cause of blindness and visual impairment, the high treatment frequency recommended by current guidelines places a significant burden on patients and healthcare providers. DESIGN: Recommended guidelines from a consensus panel. METHODS: An expert panel formed a consensus on recommendations for use of intravitreal aflibercept as treatment of nAMD in the Asia-Pacific region. RESULTS: After 3 initial monthly doses, treatment interval could be extended by 4-week increments, to a maximum of 12 weeks, in patients with inactive disease. Conversely, in active disease, treatment intervals should be shortened, by 4 weeks, or to 4 weeks in cases of severe recurrence. Treatment could be ceased in patients with stable disease activity after 12 months of treatment at 12-week intervals, as a means to prevent over treatent and lifelong injections. CONCLUSIONS: These recommendations could potentially minimize the number of treatments while maintaining efficacy and improve compliance by reducing the number of clinic visits compared with existing recommendations. Copyright 2017 Asia-Pacific Academy of Ophthalmology.
PURPOSE: To summarize recommendations for the use of intravitreal aflibercept with a treat-and-extend regimen to manage neovascular age-related macular degeneration (nAMD) in the Asia-Pacific region. Although anti-vascular endothelial growth factor therapies have improved the quality of life of patients with nAMD, a leading cause of blindness and visual impairment, the high treatment frequency recommended by current guidelines places a significant burden on patients and healthcare providers. DESIGN: Recommended guidelines from a consensus panel. METHODS: An expert panel formed a consensus on recommendations for use of intravitreal aflibercept as treatment of nAMD in the Asia-Pacific region. RESULTS: After 3 initial monthly doses, treatment interval could be extended by 4-week increments, to a maximum of 12 weeks, in patients with inactive disease. Conversely, in active disease, treatment intervals should be shortened, by 4 weeks, or to 4 weeks in cases of severe recurrence. Treatment could be ceased in patients with stable disease activity after 12 months of treatment at 12-week intervals, as a means to prevent over treatent and lifelong injections. CONCLUSIONS: These recommendations could potentially minimize the number of treatments while maintaining efficacy and improve compliance by reducing the number of clinic visits compared with existing recommendations. Copyright 2017 Asia-Pacific Academy of Ophthalmology.
Authors: Voraporn Chaikitmongkol; Min Sagong; Timothy Y Y Lai; Gavin S W Tan; Nor Fariza Ngah; Masahito Ohji; Paul Mitchell; Chang-Hao Yang; Paisan Ruamviboonsuk; Ian Wong; Taiji Sakamoto; Anand Rajendran; Youxin Chen; Dennis S C Lam; Chi-Chun Lai; Tien Yin Wong; Chui Ming Gemmy Cheung; Andrew Chang; Adrian Koh Journal: Asia Pac J Ophthalmol (Phila) Date: 2021-11-24
Authors: A García-Layana; J García-Arumí; M S Figueroa; L Arias Barquet; J M Ruíz-Moreno; L Monclús-Arbona Journal: J Ophthalmol Date: 2019-09-30 Impact factor: 1.909